Skip to content
2000
Volume 10, Issue 3
  • ISSN: 1871-5265
  • E-ISSN: 2212-3989

Abstract

Novel targets for new drug development are urgently required to combat malaria, a disease that puts half of the world's population at risk. One group of enzymes identified within the genome of the most lethal of the causative agents of malaria, Plasmodium falciparum, that may have the potential to become new targets for antimalarial drug development are the aminopeptidases. These enzymes catalyse the cleavage of the N-terminal amino acids from proteins and peptides. P. falciparum appears to encode for at least nine aminopeptidases, two neutral aminopeptidases, one aspartyl aminopeptidase, one aminopeptidase P, one prolyl aminopeptidase and four methionine aminopeptidases. Recent advances in our understanding of these genes and their protein products are outlined in this review, including their potential for antimalarial drug development.

Loading

Article metrics loading...

/content/journals/iddt/10.2174/187152610791163363
2010-06-01
2025-05-01
Loading full text...

Full text loading...

/content/journals/iddt/10.2174/187152610791163363
Loading

  • Article Type:
    Research Article
Keyword(s): aminopeptidase; drug discovery; malaria; Plasmodium falciparum
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test